Global Urinary Incontinence Therapeutics Market 2019-2023
About Urinary Incontinence
Urinary incontinence is any uncontrolled leakage of urine and this market report consists of the therapeutics used for the treatment of the diseases.
Technavio’s analysts forecast the Global Urinary Incontinence Therapeutics Market to grow at a CAGR of 3.12% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the urinary incontinence therapeutics market. To calculate the market size, the report considers the revenue generated from the application of urinary incontinence therapeutics across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global Urinary Incontinence Therapeutics Market 2019-2023
Technavio recognizes the following companies as the key players in the global urinary incontinence therapeutics market: Allergan, Astellas Pharma, Merck, Novartis, and Pfizer.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the shift toward novel formulations. Many novel formulations are being developed for the treatment of urinary incontinence and they include the transdermal therapies and mechanism-of-action (MoA)-based therapies such as bete-3- adrenergic agonists and M3 specific anticholinergics.”
According to the report, one driver influencing this market is the robust pipeline for the development of drugs for urinary incontinence treatment. Most of the urinary incontinence therapeutics that are currently in Phase III stage are likely to get approved during the forecast period to augment the growth of the global urinary incontinence market. Furthermore, the increasing number of molecules being developed for urinary incontinence treatment will drive the demand for urinary incontinence therapeutics across the period of forecast.
Further, the report states that one challenge affecting this market is the patent expiries of drugs. Since generic drugs are copies of branded drugs, they can be independently developed only after the expiry of patents of the original products which may impede the growth of the market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook